GILD
GILEAD SCIENCES, INC.
NASDAQ · Healthcare · Drug Manufacturers - General · US
$156.19
−0.75%Price chart
Sep 17Sep 22Sep 25Sep 30Oct 5Oct 8Oct 13Oct 16
Key dataOct 16, 2026
Open$157.32
From 52W high−0.75%
Volume7.76M
Market cap$193.67B
P/E (TTM)—
P/S (TTM)6.4x
Div yield1.58%
Key dataOct 16, 2026
Open
$157.32
From 52W high
−0.75%
Volume
7.76M
Market cap
$193.67B
ValuationView details →
P/E (Fwd)
16.4x
EV/EBITDA
162.4x
P/E (TTM)
—
RSI (14)
64.3
MomentumView details →
1D Return
−0.75%
YTD Return
+27.57%
SummaryUpdated Jun 1, 2026
Gilead Sciences, Inc. (NASDAQ:GILD) is a leading biopharmaceutical company founded in 1987 and headquartered in Foster City, California. The company went public in 1992 and has established itself as a major player in the pharmaceutical industry, particularly known for its groundbreaking treatments in HIV/AIDS, hepatitis, and oncology. Gilead has built its reputation through innovative drug discovery and development, with a focus on addressing unmet medical needs in serious diseases. The company operates globally, serving patients in the United States, Europe, and international markets through its comprehensive portfolio of specialized medicines.
Similar companies
Latest newsMore news →
GILEAD SCIENCES, INC. closed at $157.48, up 2.57% from the previous trading session.21h agoThe listed top gainers included Perrigo, up 3.77%; GILEAD SCIENCES, INC., up 3.8%; Kroger, up 3.87%; BRISTOL MYERS SQUIBB CO, up 4.61%; and UNITEDHEALTH GROUP INC, up 4.73%.2d agoGilead Sciences (GILD) shares fell 1.87% to close at $144.74 on the most recent trading day.14d ago